Sugi Predict

Sugi Predict / Compounds / SCHEMBL21106900

SCHEMBL21106900

SCHEMBL21106900

CN[C@@H](C)C(=O)NC(C(=O)N1CCC[C@H]1c1nc(C(=O)c2ccccc2)cs1)C1CCCCC1

nearest known ligand 0.48

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ BIRC2 Q13490 12/20 0.48
▸ XIAP P98170 12/20 0.47
▸ BIRC3 Q13489 5/20 0.47
▸ RIPK2 O43353 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21471950 1.00 BIRC2 (0.48) BIRC2XIAPBIRC3RIPK2
SCHEMBL1357580 1.00 BIRC2 (0.48) BIRC2XIAPBIRC3RIPK2
SCHEMBL21471951 1.00 BIRC2 (0.48) BIRC2XIAPBIRC3RIPK2
SCHEMBL28788354 1.00 BIRC2 (0.48) BIRC2XIAPBIRC3RIPK2
SCHEMBL29312021 0.93 BIRC2 (0.46) BIRC2XIAPBIRC3RIPK2
SCHEMBL23572024 0.92 TRPV1 (0.42) BIRC2XIAPBIRC3
Lcl-161 SCHEMBL21064744 0.92 XIAP (0.50) BIRC2XIAPBIRC3RIPK2
Lcl-161 SCHEMBL1275554 0.92 XIAP (0.50) BIRC2XIAPBIRC3RIPK2
Lcl-161 SCHEMBL19164873 0.92 XIAP (0.50) BIRC2XIAPBIRC3RIPK2
Lcl-161 SCHEMBL3688581 0.92 XIAP (0.50) BIRC2XIAPBIRC3RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
WO-2022087216-A1 DOUBLE DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-04-28 — — WO disclosed
WO-2021011868-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-01-21 — — WO disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 BIRC2 218/4885XIAP 74/4885BIRC3 144/4885
US-20230132715-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BIRC2 218/4885XIAP 74/4885BIRC3 144/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 BIRC2 218/4885XIAP 74/4885BIRC3 144/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BIRC2 218/4885XIAP 74/4885BIRC3 144/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 BIRC2 218/4885XIAP 74/4885BIRC3 144/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 BIRC2 218/4885XIAP 74/4885BIRC3 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.